This review highlights advances in the role of ACE inhibitors for hypertension and heart failure to develop a rational prescribing approach.
May guide ACE inhibitor prescribing in hypertension and HF; leaves open need for prospective validation of advances.
SUMMARY Angiotensin‐converting enzyme (ACE) inhibitors are now widely prescribed for the treatment of hypertension and heart failure. Their increasing popularity is based on impressive results from studies of efficacy in clinical situations and the realisation that they may have advantages over conventional treatment. This review will highlight some of the recent advances in our knowledge of the role of ACE inhibitors and will develop a rational approach to prescribing.
No takes yet. Share an insight, caveat, or question.
Maxwell et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: